Anti-SARS-CoV-2 IgG Seroprevalence in Tyrol, Austria, among 28,768 Blood Donors between May 2022 and March 2023
Vaccines (Basel). 2024 Mar 8;12(3):284. doi: 10.3390/vaccines12030284.
PMID:
SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023
Nat Commun. 2024 Jul 11;15(1):5847. doi: 10.1038/s41467-024-50052-2.
PMID:
Increased efficacy of influenza virus vaccine candidate through display of recombinant neuraminidase on virus like particles
Front Immunol. 2024 Jun 10;15:1425842. doi: 10.3389/fimmu.2024.1425842. eCollection 2024.
PMID:
Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase
mBio. 2024 Jul 17;15(7):e0108524. doi: 10.1128/mbio.01085-24. Epub 2024 Jun 20.
PMID:
Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland
Respiration. 2024;103(9):593-600. doi: 10.1159/000539410. Epub 2024 May 29.
PMID:
Detection of clade 2.3.4.4b highly pathogenic H5N1 influenza virus in New York City
J Virol. 2024 Jun 13;98(6):e0062624. doi: 10.1128/jvi.00626-24. Epub 2024 May 15.
PMID:
Humoral correlates of protection against influenza A H3N2 virus infection
J Infect Dis. 2024 May 9:jiae258. doi: 10.1093/infdis/jiae258. Online ahead of print.
PMID:
Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality
J Clin Invest. 2024 May 1;134(9):e176640. doi: 10.1172/JCI176640.
PMID:
Detection of clade 2.3.4.4b highly pathogenic H5N1 influenza virus in New York City
bioRxiv [Preprint]. 2024 Apr 4:2024.04.04.588061. doi: 10.1101/2024.04.04.588061.
PMID:
An ELISA-Based Method to Measure Mucosal Antibody Responses Against SARS-CoV-2 in Human Saliva
Curr Protoc. 2024 Apr;4(4):e1024. doi: 10.1002/cpz1.1024.
PMID: